These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1245 related articles for article (PubMed ID: 18662762)

  • 1. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
    Sayin B; Somavarapu S; Li XW; Sesardic D; Senel S; Alpar OH
    Eur J Pharm Sci; 2009 Nov; 38(4):362-9. PubMed ID: 19733658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
    Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
    J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
    Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
    Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
    J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
    Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.
    Chen F; Zhang ZR; Yuan F; Qin X; Wang M; Huang Y
    Int J Pharm; 2008 Feb; 349(1-2):226-33. PubMed ID: 17825506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
    Pirouzmand H; Khameneh B; Tafaghodi M
    Pharm Biol; 2017 Dec; 55(1):212-217. PubMed ID: 27927058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
    Sadeghi AM; Dorkoosh FA; Avadi MR; Weinhold M; Bayat A; Delie F; Gurny R; Larijani B; Rafiee-Tehrani M; Junginger HE
    Eur J Pharm Biopharm; 2008 Sep; 70(1):270-8. PubMed ID: 18492606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization.
    Jain S; Sharma RK; Vyas SP
    J Pharm Pharmacol; 2006 Mar; 58(3):303-10. PubMed ID: 16536896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies.
    Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
    Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
    Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies.
    Zheng Y; Cai Z; Song X; Chen Q; Bi Y; Li Y; Hou S
    J Drug Target; 2009 May; 17(4):294-303. PubMed ID: 19255895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice.
    Jiang L; Qian F; He X; Wang F; Ren D; He Y; Li K; Sun S; Yin C
    J Gene Med; 2007 Apr; 9(4):253-64. PubMed ID: 17397104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
    Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
    J Pharm Sci; 2014 Nov; 103(11):3448-3456. PubMed ID: 25219511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.